IN8bio’s Vision for the Future of Immunotherapy at 2025 Events
IN8bio to Showcase Innovations at Immuno-Oncology 360° Conference
IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company, is set to make waves at the Immuno-Oncology 360° (IO360°) Conference scheduled for March 24-26, 2025. This prestigious gathering in Boston will bring together experts to explore cutting-edge advancements in cancer therapies, particularly focusing on innovative gamma-delta T cell approaches for treating various diseases.
Key Participation Highlights
William Ho, the Chief Executive Officer and a co-founder of IN8bio, will take a prominent role as Co-Chair of Day 2 of the conference commencing at 8:15 AM EDT on March 25, 2025. His influential presence will be marked by welcoming remarks and a session dedicated to exploring complex questions surrounding immuno-oncology for autoimmunity diseases.
Exploring Critical Topics in Autoimmunity
As the conference unfolds, Mr. Ho will lead a significant discussion titled “Tackling the Tough Questions in IO for Autoimmunity Disease.” This segment aims to shed light on the challenges and strategies impacting the development of immunotherapies targeting autoimmune conditions. Continuing in the afternoon session, he is scheduled to present at 4:35 PM EDT on the essential theme of the “Gamma-Delta T Cell Engager” and details on IN8bio's promising INB-619 T cell engager program.
Discussion of Market Trends
In his role as Co-Chair and panelist, Mr. Ho is keen to articulate the rationale for utilizing gamma-delta T cell engagers in the pursuit of combating autoimmunity—an area that is fast becoming a focal point for immunotherapy developments. These discussions will likely cover not just the current state but also investments and business strategies shaping the landscape of immuno-oncology.
Presentations to Look Forward To
Highlighting the importance of effective discourse, details for the presentations include:
Co-Chairs' Welcome & Tackling the Tough Questions in IO for Autoimmunity Disease
Date/Time: March 25, 2025, at 8:15 AM EDT
Picking Our Horse in the Race for Autoimmunity: The Gamma-Delta T Cell Engager
Date/Time: March 25, 2025, at 4:35 PM EDT
Networking Opportunities
For those looking to engage directly with IN8bio representatives during the conference, they are encouraged to coordinate meetings to discuss innovative therapies and collaboration opportunities in the immunotherapy sector. Interested individuals should reach out to the company via email to facilitate scheduling.
To explore more about the conference and its offerings, you can visit the event's official website.
About IN8bio and Its Prominent Role
IN8bio is at the forefront of developing gamma-delta T cell-based immunotherapies specifically tailored for cancer therapy. This innovative approach leverages the unique abilities of gamma-delta T cells, providing a distinctive edge in distinguishing healthy tissues from diseased ones. Their flagship program, INB-100, focuses on acute myeloid leukemia, optimally employing haplo-matched allogeneic gamma-delta T cells for effective post-transplant treatment.
Advancements are also being made with autologous DeltEx DRI gamma-delta T cells for glioblastoma, combined with standard care protocols, aimed at enhancing patient outcomes. IN8bio continues to progress novel gamma-delta T cell engagers, potentially addressing both oncology and autoimmune conditions.
Contact Information for Investors and Interested Parties
For further inquiries, potential investors, or media contacts, information is available for Glenn Schulman, as well as other representatives at IN8bio, ensuring robust communication channels for engagement and transparency.
Frequently Asked Questions
What is the Immuno-Oncology 360° Conference?
The Immuno-Oncology 360° Conference is an event that focuses on the latest advancements in the field of immunotherapy, bringing together industry leaders and innovators.
Who is William Ho?
William Ho is the CEO and co-founder of IN8bio, a company specializing in developing novel gamma-delta T cell therapies for oncology and autoimmune diseases.
What will Mr. Ho discuss at the conference?
Mr. Ho will address the challenges in immunotherapy for autoimmunity and highlight IN8bio’s innovative programs, including their gamma-delta T cell engagers.
What is INB-619?
INB-619 is IN8bio's T cell engager program aimed at targeting oncology and autoimmune diseases using gamma-delta T cell technology.
How can I contact IN8bio?
Interested parties can reach out to IN8bio representatives via the provided email addresses for inquiries regarding their therapies and potential collaborations.
About The Author
Contact Hannah Lewis privately here. Or send an email with ATTN: Hannah Lewis as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
